The role of statin therapy in prostate cancer (PCa) prevention and treatment is plagued by controversy.
This critical review of published clinical series reveals several caveats in earlier studies, which reported no benefit. Recent studies that adjust for confounding factors have demonstrated statin therapy to be associated with PCa prevention and favorable clinical outcomes. Developed as inhibitors of cholesterol synthesis, the expected mechanism of statin action is systemic cholesterol reduction. By lowering circulating cholesterol, statins indirectly reduce cellular cholesterol levels in multiple cell types, impacting on membrane microdomains and steroidogenesis. Although non-cholesterol mechanisms of statin action have been proposed, they are limited by the uncertainties surrounding in vivo tissue statin concentrations.
Written by:
Moon H, Hill MM, Roberts MJ, Gardiner RA, Brown AJ. Are you the author?
The University of Queensland Diamantina Institute, The University of Queensland, Translational Research Institute, Brisbane, QLD 4102, Australia; The University of Queensland Centre for Clinical Research, The University of Queensland, Brisbane, QLD 4006, Australia; Department of Urology, Royal Brisbane and Women's Hospital, Brisbane, QLD 4006, Australia; School of Medicine, The University of Queensland, Brisbane, QLD 4006, Australia; School of Biotechnology and Biomolecular Sciences, The University of New South Wales, Sydney, NSW 2052, Australia.
Reference: Trends Endocrinol Metab. 2014 Jan 22. pii: S1043-2760(13)00215-4.
doi: 10.1016/j.tem.2013.12.007
PubMed Abstract
PMID: 24462080
UroToday.com Prostate Cancer Section
